This transcript discusses a research collaboration involving the processing of over 200 circulating tumor DNA (ctDNA) samples since July 2022. Due to the extremely small quantity of ctDNA per sample, each sample could only be run once for library preparation. The team utilized the Avenio VGE platform, which proved to be highly reliable, instilling significant confidence for successful future ctDNA projects despite the limited sample availability.
Summary of Transcript:
0:00 Collaboration and Sample Acquisition: The team received over 200 circulating tumor DNA (ctDNA) samples from a collaborator starting in July 2022.
0:18 Sample Quantity Challenge: The amount of ctDNA available per sample was very small, meaning there was only one opportunity to perform library preparation.
0:26 Avenio VGE Reliability: The Avenio VGE platform was used for library preparation, demonstrating high reliability and ensuring successful processing of the precious ctDNA samples.
0:34 Future Confidence: The success with the 200+ samples has built strong confidence for undertaking future ctDNA projects with the Avenio VGE, despite the inherent challenges of limited sample material.